Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial-Reference-Cited by-同舟云学术

Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial

Published:2019-09 Issue:17 Volume:93 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Zolla-Pazner Susan¹^ORCID,Gilbert Peter B.²

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA

2. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center and Department of Biostatistics, University of Washington, Seattle, Washington, USA

Abstract

The RV144 vaccine trial is the only clinical study to have shown a modest but statistically significant decrease in HIV infection risk. RV144 and the subsequent studies identifying the level of V1V2-specific antibodies as a correlate of reduced infection risk are still controversial despite many papers supporting and expanding the initial study.

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/JVI.00629-19

Reference40 articles.

1. HIV vaccine design and the neutralizing antibody problem

2. Beyond Thailand: Making Sense of a Qualified AIDS Vaccine "Success"

3. Cohen J. 2009. Unrevealed analysis weakens claim of AIDS vaccine “success”. Sci Insider, vol 362.